Literature DB >> 26764429

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.

S Kaatz1, D Ahmad2, A C Spyropoulos3, S Schulman4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26764429     DOI： 10.1111/jth.13140

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  223 in total

Review 1.  Breadth of complications of long-term oral anticoagulant care.

Authors:  Walter Ageno; Marco Donadini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge.

Authors:  Amanda N Basto; Nathan P Fewel; Kim Vo; Eileen M Stock; Mia Ta
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

3.  Clinically relevant non-major bleeding with oral anticoagulants: non-major may not be trivial.

Authors:  Laura Franco; Cecilia Becattini; Simone Vanni; Rodolfo Sbrojavacca; Cinzia Nitti; Giorgia Manina; Luca Masotti; Fulvio Pomero; Sergio Cattinelli; Roberto Cappelli; Roberta Re; Giancarlo Agnelli
Journal:  Blood Transfus       Date:  2017-03-15       Impact factor: 3.443

4.  Clinical experience reversing factor Xa inhibitors with four-factor prothrombin complex concentrate in a community hospital.

Authors:  Katie B Tellor; Naomi S Barasch; Brian M Lee
Journal:  Blood Transfus       Date:  2017-01-24       Impact factor: 3.443

5.  The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding.

Authors:  Sarah Hanigan; Jessica Das; Kristen Pogue; Geoffrey D Barnes; Michael P Dorsch
Journal:  J Thromb Thrombolysis       Date:  2020-05       Impact factor: 2.300

6.  Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans.

Authors:  Carmen P Escalante; Gregory W Gladish; Wei Qiao; Ali Zalpour; Binara Assylbekova; Shuwei Gao; Kelechi A Olejeme; Marsha N Richardson; Maria E Suarez-Almazor
Journal:  Support Care Cancer       Date:  2017-01-09       Impact factor: 3.603

7.  Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia.

Authors:  Damien Gheldof; Hélène Haguet; Jean-Michel Dogné; Céline Bouvy; Carlos Graux; Fabienne George; Anne Sonet; Christian Chatelain; Bernard Chatelain; François Mullier
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

8.  Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort.

Authors:  Patrick Ellsworth; Sheh-Li Chen; Raj S Kasthuri; Nigel S Key; Micah J Mooberry; Alice D Ma
Journal:  Blood Adv       Date:  2020-12-22

9.  Secondary Anticoagulation Prophylaxis for Catheter-Related Thrombosis in Pediatric Intestinal Failure: Comparison of Short- Vs Long-Term Treatment Protocols.

Authors:  Melanie Lissa Schmidt; Danielle Wendel; Simon Peter Horslen; Erin Richardson Lane; Leonardo Rodrigues Brandão; Emily Gottschalk; Christina Belza; Glenda Courtney-Martin; Paul William Wales; Yaron Avitzur
Journal:  JPEN J Parenter Enteral Nutr       Date:  2020-12-06       Impact factor: 4.016

10.  A multicentre controlled pre-post trial of an implementation science intervention to improve venous thromboembolism prophylaxis in critically ill patients.

Authors:  Henry T Stelfox; Rebecca Brundin-Mather; Andrea Soo; Jeanna Parsons Leigh; Daniel J Niven; Kirsten M Fiest; Christopher James Doig; Danny J Zuege; Barry Kushner; Fiona Clement; Sharon E Straus; Deborah J Cook; Sean M Bagshaw; Khara M Sauro
Journal:  Intensive Care Med       Date:  2019-02-01       Impact factor: 17.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.